Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY3154885 + itraconazole
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination refers to the **co-administration of LY3154885, a dopamine D1 receptor positive allosteric modulator (PAM), and itraconazole, an azole antifungal and potent CYP3A4 inhibitor**. LY3154885 is an experimental small molecule developed for neurological disorders, metabolized primarily by UGT rather than CYP3A4, aiming to reduce drug-drug interaction risk compared to earlier compounds. Itraconazole is a clinically approved antifungal used to treat mycotic infections and is a strong inhibitor of CYP3A4 and certain drug transporters. This combination is not a marketed product, but rather a regimen studied in Phase 1 trials to assess how itraconazole affects the pharmacokinetics and safety profile of LY3154885 due to its CYP3A4 inhibition[1][3][4][5][2][8].
- Brand names
- Sporanoz
- Other names
- itraconazoleLY-3154885LY3154885LY 3154885compound 5compound5compound-5
02
Targets
DRD1 (Dopamine D1 Receptor)CYP51A1 (Sterol 14α-demethylase)CYP3A (CYP3A family)
Beyond the preview
Go deeper on LY3154885 + itraconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY3154885 + itraconazole.